We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Oruba Showcases Innovative Self-Operating Uroflowmeter

By LabMedica International staff writers
Posted on 12 Nov 2024
Print article
Image: Oruba Technology is showcasing its innovative self-operating uroflowmeter at MEDICA 2024 (Photo courtesy of Oruba)
Image: Oruba Technology is showcasing its innovative self-operating uroflowmeter at MEDICA 2024 (Photo courtesy of Oruba)

Oruba Technology & Innovation (Langenfeld, Germany) is showcasing its innovative self-operating uroflowmeter, Oruflow, including both the urinal and toilet versions, at MEDICA 2024.

Oruflow is the world’s first self-operating uroflowmeter. As a point-of-care (POC) diagnostic device, it eases and accelerates the uroflowmetry process in a hygienic and comfortable atmosphere, making it a crucial part of every hospital and urology clinic. Oruba Oruflow is available in two versions for urology clinics – the Oruflow i POC diagnostic urinal and the Oruflow h POC diagnostic toilet. Both the devices feature an on-board screen to assist patients before and after examinations. The patient can receive the results of the examination in seconds without any operator guidance. The patient uses the hospital barcode to let Oruba Oruflow save the examination report into the hospital information system automatically.

The Oruflow h features a specially designed adapter enabling accurate and comfortable uroflowmetry testing for individuals of all gender types and ages. This ergonomic adapter is designed to accommodate anatomical differences such as the urination posture of women, ensuring a seamless and user-friendly experience. This adaptor is also suitable for children, providing the same level of comfort and accuracy. Oruflow h introduces a groundbreaking feature: The anatomical design of the toilet which separates stool and urine. With this feature, Oruflow h continues working even after accidental defecation, ensuring reliable performance in all conditions.

Both the Oruflow models have an EMG (electromyography) option, which provides synchronized uroflowmetry and EMG measurements. While the Oruflow measures the urine flow rate, the EMG module measures the electrical activity of the muscles before, during, and after urination to evaluate urinary problems. In biofeedback, EMG results are displayed using a bird game interface which is also virtual reality-compatible. When the patient contracts their muscles, the bird flaps. The doctor can change the scale and see the results synchronously.

Related Links:
Oruba Technology & Innovation

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The study demonstrated that electric-field molecular fingerprinting can probe cancer (Photo courtesy of ACS Central Science, 2025, 10.1021/acscentsci.4c02164)

New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma

Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read more

Molecular Diagnostics

view channel
Image: The study validated the Lumipulse p-tau21 automated and scalable blood test system (Photo courtesy of Fujirebio)

Blood Test for Early Alzheimer's Detection Achieves Over 90% Accuracy

Alzheimer's disease (AD) is a debilitating condition and a leading cause of disability and death worldwide. The availability of reliable diagnostic tools is currently restricted, and diagnosis often relies... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.